Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HTR1F | P30939 | 5/20 | 0.55 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | HTR1D | P28221 | 3/20 | 0.55 |
| ▸ | HTR1B | P28222 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3248051 | 0.99 | RAB9A (0.57) | RAB9ANPC1TP53ALOX15MAPK1 | |
| SCHEMBL3247945 | 0.89 | KMT2A (0.55) | RAB9ANPC1TP53ALOX15MAPK1 | |
| SCHEMBL3248759 | 0.89 | ALDH1A1 (0.53) | RAB9ANPC1TP53ALOX15MAPK1 | |
| SCHEMBL3242563 | 0.88 | RAB9A (0.56) | RAB9ANPC1TP53HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3247483 | 0.88 | KMT2A (0.54) | RAB9ANPC1TP53ALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL3245119 | 0.87 | RAB9A (0.54) | RAB9ANPC1TP53HTTSMN1; SMN2 | |
| SCHEMBL3248661 | 0.87 | NPC1 (0.62) | RAB9ANPC1TP53HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3249774 | 0.86 | NPC1 (0.61) | RAB9ANPC1TP53HTTSMN1; SMN2 | |
| SCHEMBL3248427 | 0.85 | DPP4 (0.54) | RAB9ANPC1TP53ALOX15MAPK1 | |
| SCHEMBL3252139 | 0.85 | RAB9A (0.61) | RAB9ANPC1TP53ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236793-B2 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NEUROSEARCH A/S (DK) | 2012-08-07 | — | — | US | claimed |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | ANIONA APS (DK) | 2010-05-06 | — | — | US | claimed |
| EP-1713487-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2009-12-02 | — | — | EP | claimed |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | ANIONA APS (DK) | 2008-09-18 | — | — | US | claimed |
| US-8236793-B2 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NEUROSEARCH A/S (DK) | 2012-08-07 | — | — | US | disclosed |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | ANIONA APS (DK) | 2010-05-06 | — | — | US | disclosed |
| EP-2172469-A1 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NeuroSearch A/S (DK) | 2010-04-07 | — | — | EP | disclosed |
| US-7662808-B2 | N-[4-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-phenyl]-benzamide; disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| EP-1713487-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2009-12-02 | — | — | EP | disclosed |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | ANIONA APS (DK) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | CHRNA6, CHRNA10, CHRNA2 | RAB9A 2916/4885NPC1 1787/4885TP53 4761/4885 |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | CHRNA6, CHRNA10, CHRNA2 | RAB9A 2958/4885NPC1 1780/4885TP53 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.